EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early real-world use of acoramidis for transthyretin amyloid cardiomyopathy in Germany: results from StarTTR

Caroline Morbach, Christoph Ohlmeier, Teresa Trenkwalder, Fabian Aus dem Siepen, Silvia Kruppert, Gereon Keuken, Thomas Evers, Roman Pfister, Stefan Herrmann, Stefan Störk

Clinical Research in Cardiology · 02.11.2026

DOI: 10.1007/s00392-026-03023-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 02.11.2026. Verfasst von Caroline Morbach und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany. Morbach_C@ukw.de. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG, Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acoramidis, a selective transthyretin stabilizer, received EU approval in February 2025 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). We describe patient characteristics and comedication patterns in German routine care.

Methods

Adults with ≥ 1 acoramidis dispensation between April and September 2025 were identified from the IQVIA™ Longitudinal Prescription database, which covers 82% of reimbursed prescriptions. Sociodemographic data, comorbidities, prescribing setting, and comedications were analyzed overall and by pretreatment status (treatment-naïve vs. tafamidis switchers).

Results

A total of 289 patients were identified; median age was 82 (interquartile range 77–85) years; 15% were female and 86% were treatment-naïve. Acoramidis initiation occurred predominantly in hospital outpatient departments (87%). In the year preceding initiation, the most common comedications were renin–angiotensin system (RAS) inhibitors (76%), sodium glucose cotransporter 2 (SGLT2) inhibitors (74%), and beta-blockers (71%). Between 12 and 10 months and 3 and 1 months before initiation, use of mineralocorticoid receptor antagonists (MRAs), loop diuretics, direct oral anticoagulants, and SGLT2 inhibitors increased markedly, whereas RAS inhibitors, beta-blockers, and calcium channel blockers remained unchanged.

Conclusion

This real-world analysis showed that acoramidis was predominantly prescribed as first-line therapy for older, mainly male patients with ATTR-CM; switching from tafamidis was comparatively infrequent. The increasing use of MRAs, loop diuretics, direct oral anticoagulants, and SGLT2 inhibitors prior to acoramidis initiation is consistent with active therapeutic optimization in specialist centers. These data provide an early benchmark for monitoring acoramidis adoption and will inform future comparative effectiveness research. Graphical Abstract

Schlagwörter

Stichwörter der Autor:innen

ATTR-CMAcoramidisReal worldTTR stabilizer

Autor:innen und Institutionen

  • Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany. Morbach_C@ukw.de.
  • Department of Medicine I, University Hospital Würzburg, Würzburg, Germany. Morbach_C@ukw.de.
  • Bayer AG, Berlin, Germany.
  • Department of Cardiology, TUM University Hospital, German Heart Center, Munich, Germany.
  • University Heidelberg, Heidelberg, Germany.
  • IQVIA, Frankfurt, Germany.

Förderung

  • Bayer AG
  • Universitätsklinikum Würzburg

Zitieren

APA

Morbach, C., Ohlmeier, C., Trenkwalder, T., Aus dem Siepen, F., Kruppert, S., Keuken, G., Evers, T., Pfister, R., Herrmann, S., & Störk, S. (2026). Early real-world use of acoramidis for transthyretin amyloid cardiomyopathy in Germany: results from StarTTR. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03023-0

Vancouver

Morbach C, Ohlmeier C, Trenkwalder T, Aus dem Siepen F, Kruppert S, Keuken G, et al. Early real-world use of acoramidis for transthyretin amyloid cardiomyopathy in Germany: results from StarTTR. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-03023-0

BibTeX
@article{Morbach2026,
  author = {Morbach, Caroline and Ohlmeier, Christoph and Trenkwalder, Teresa and Aus dem Siepen, Fabian and Kruppert, Silvia and Keuken, Gereon and Evers, Thomas and Pfister, Roman and Herrmann, Stefan and Störk, Stefan},
  title = {Early real-world use of acoramidis for transthyretin amyloid cardiomyopathy in Germany: results from StarTTR},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-026-03023-0}
}
Kostenlos starten →